CD80 Rabbit Polyclonal Antibody
CD80 Rabbit Polyclonal Antibody
![]() CD80 Polyclonal Antibody |
|||
ES8772-100ul | ELK Biotech | 100ul | 334.8 EUR |
Description: A Rabbit Polyclonal antibody against CD80 from Human. This antibody is tested and validated for IHC, WB, ELISA |
|||
![]() CD80 Polyclonal Antibody |
|||
ES8772-50ul | ELK Biotech | 50ul | 248.4 EUR |
Description: A Rabbit Polyclonal antibody against CD80 from Human. This antibody is tested and validated for IHC, WB, ELISA |
|||
![]() CD80 Rabbit pAb |
|||
A16039-100ul | Abclonal | 100 ul | 369.6 EUR |
![]() CD80 Rabbit pAb |
|||
A16039-200ul | Abclonal | 200 ul | 550.8 EUR |
![]() CD80 Rabbit pAb |
|||
A16039-20ul | Abclonal | 20 ul | 219.6 EUR |
![]() CD80 Rabbit pAb |
|||
A16039-50ul | Abclonal | 50 ul | 267.6 EUR |
![]() CD80 Rabbit mAb |
|||
A19025-100ul | Abclonal | 100 ul | 492 EUR |
![]() CD80 Rabbit mAb |
|||
A19025-200ul | Abclonal | 200 ul | 685.2 EUR |
![]() CD80 Rabbit mAb |
|||
A19025-20ul | Abclonal | 20 ul | 265.2 EUR |
![]() CD80 Rabbit mAb |
|||
A19025-50ul | Abclonal | 50 ul | 344.4 EUR |
![]() CD80 Antibody |
|||
1-CSB-PA129040 | Cusabio |
|
|
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000 |
|||
![]() CD80 Antibody |
|||
1-CSB-PA130815 | Cusabio |
|
|
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100 |
|||
![]() CD80 Antibody |
|||
1-CSB-PA277650 | Cusabio |
|
|
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
|||
![]() CD80 Antibody |
|||
1-CSB-PA004959GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
|||
![]() CD80 Antibody |
|||
DF7682 | Affbiotech | 200ul | 420 EUR |
![]() CD80 antibody |
|||
70R-35657 | Fitzgerald | 100 ug | 418.8 EUR |
Description: Rabbit polyclonal CD80 antibody |
|||
![]() CD80 Antibody |
|||
49409-100ul | SAB | 100ul | 399.6 EUR |
![]() CD80 Antibody |
|||
49409-50ul | SAB | 50ul | 286.8 EUR |
![]() CD80 antibody |
|||
70R-13908 | Fitzgerald | 100 ug | 386.4 EUR |
Description: Affinity purified Mouse polyclonal CD80 antibody |
|||
![]() CD80 Antibody |
|||
37436-100ul | SAB | 100ul | 302.4 EUR |
![]() CD80 antibody |
|||
10R-6436 | Fitzgerald | 100 ug | 282 EUR |
Description: Armenian Hamster monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-6437 | Fitzgerald | 100 ug | 230.4 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-6844 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-7741 | Fitzgerald | 500 ug | 678 EUR |
Description: Rat monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-1912 | Fitzgerald | 100 ul | 483.6 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-CD80bMS | Fitzgerald | 500 ug | 444 EUR |
Description: Rat monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3627 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3628 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3629 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3630 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3631 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3632 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3634 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 antibody |
|||
10R-3635 | Fitzgerald | 100 ul | 829.2 EUR |
Description: Mouse monoclonal CD80 antibody |
|||
![]() CD80 Antibody |
|||
ABD7682 | Lifescience Market | 100 ug | 525.6 EUR |
![]() CD80 Antibody |
|||
ABD8145 | Lifescience Market | 100 ug | 525.6 EUR |
![]() CD80 Antibody |
|||
8679-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody |
|||
8679-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 antibody |
|||
PAab09813 | Lifescience Market | 100 ug | 463.2 EUR |
![]() CD80 Antibody |
|||
R30433 | NSJ Bioreagents | 100 ug | 419 EUR |
![]() CD80 Antibody |
|||
R30434 | NSJ Bioreagents | 100 ug | 419 EUR |
![]() CD80 Antibody |
|||
R34234-100UG | NSJ Bioreagents | 100 ug | 399 EUR |
![]() CD80 Antibody |
|||
RQ4248 | NSJ Bioreagents | 100 ug | 419 EUR |
![]() CD80 Antibody |
|||
V8234-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V8234-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V8234SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V8522-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
RQ6838 | NSJ Bioreagents | 100ug | 419 EUR |
Description: Cluster of Differentiation 80 (also CD80 and B7-1) is a protein found on activated B cells and monocytes that provides a costimulatory signal necessary for T cell activation and survival. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. The CD80 genes encode B7-1 which are structurally similar members of the immunoglobulin superfamily expressed on a variety of hematopoietic cell types. |
|||
![]() CD80 Antibody |
|||
F48980-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() CD80 Antibody |
|||
F48980-0.4ML | NSJ Bioreagents | 0.4 ml | 379 EUR |
![]() CD80 Antibody |
|||
V7382-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V7382-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V7382IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V7382SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V7498-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V7498-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V7498SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V3297-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V3297-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V3297SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V8522-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() CD80 Antibody |
|||
V8522SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell. |
|||
![]() Polyclonal CD80 Antibody (internal region) |
|||
APR11032G | Leading Biology | 0.1 mg | 580.8 EUR |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human CD80 (internal region). This antibody is tested and proven to work in the following applications: |
|||
![]() Rabbit T- lymphocyte activation antigen CD80, CD80 ELISA KIT |
|||
ELI-06510Ra | Lifescience Market | 96 Tests | 1113.6 EUR |
![]() Anti-CD80/B7 1 Rabbit Monoclonal Antibody |
|||
M00196 | BosterBio | 100ug/vial | 476.4 EUR |
Description: Rabbit Monoclonal CD80/B7 1 Antibody. Validated in IHC, WB and tested in Human. |
|||
![]() CD80 |
|||
80A-100T | ImmunoStep | 100 test | 450 EUR |
![]() CD80 |
|||
80F-100T | ImmunoStep | 100 test | 372 EUR |
![]() CD80 |
|||
80PE-100T | ImmunoStep | 100 test | 762 EUR |
![]() CD80 |
|||
MO80A(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80A(V25) | ImmunoStep | 25 ug | 60 EUR |
![]() CD80 |
|||
MO80B(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80B(V25) | ImmunoStep | 25 ug | 60 EUR |
![]() CD80 |
|||
MO80CFB(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80CFB(V25) | ImmunoStep | 25 ug | 60 EUR |
![]() CD80 |
|||
MO80F(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80F(V25) | ImmunoStep | 25 ug | 60 EUR |
![]() CD80 |
|||
MO80F(V500) | ImmunoStep | 500 ug | 60 EUR |
![]() CD80 |
|||
MO80PE(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80PE(V25) | ImmunoStep | 25 ug | 60 EUR |
![]() CD80 |
|||
MO80PP(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80PP(V25) | ImmunoStep | 25 ug | 60 EUR |
![]() CD80 |
|||
MO80PP5.5(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80PP5.5(V25) | ImmunoStep | 25 ug | 60 EUR |
![]() CD80 |
|||
MO80PU(V100) | ImmunoStep | 100 ug | 60 EUR |
![]() CD80 |
|||
MO80PU(V500) | ImmunoStep | 500 ug | 60 EUR |
![]() Polyclonal CD80 antibody - C-terminal region |
|||
APR11033G | Leading Biology | 0.05mg | 633.6 EUR |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD80 - C-terminal region. This antibody is tested and proven to work in the following applications: |
|||
![]() T-lymphocyte activation antigen CD80 (CD80) Antibody |
|||
20-abx019054 | Abbexa |
|
|
![]() CD80 Conjugated Antibody |
|||
C49409 | SAB | 100ul | 476.4 EUR |
![]() anti- CD80 antibody |
|||
FNab01500 | FN Test | 100µg | 658.5 EUR |
Description: Antibody raised against CD80 |
|||
![]() CD80 antibody (FITC) |
|||
61R-1108 | Fitzgerald | 100 ug | 360 EUR |
Description: Armenian Hamster monoclonal CD80 antibody (FITC) |
|||
![]() CD80 antibody (PE) |
|||
61R-1274 | Fitzgerald | 100 ug | 379.2 EUR |
Description: Mouse monoclonal CD80 antibody (PE) |
|||
![]() CD80 antibody (PE) |
|||
61R-1275 | Fitzgerald | 100 ug | 424.8 EUR |
Description: Armenian Hamster monoclonal CD80 antibody (PE) |
|||
![]() CD80 antibody (PE) |
|||
61R-1276 | Fitzgerald | 100 tests | 463.2 EUR |
Description: Mouse monoclonal CD80 antibody (PE) |
|||
![]() CD80 antibody (biotin) |
|||
61R-1527 | Fitzgerald | 100 ug | 379.2 EUR |
Description: Mouse monoclonal CD80 antibody (biotin) |
|||
![]() CD80 antibody (biotin) |
|||
61R-1528 | Fitzgerald | 100 ug | 340.8 EUR |
Description: Armenian Hamster monoclonal CD80 antibody (biotin) |
|||
![]() CD80 antibody (biotin) |
|||
61R-1529 | Fitzgerald | 100 ug | 379.2 EUR |
Description: Mouse monoclonal CD80 antibody (biotin) |
|||
![]() CD80 antibody (allophycocyanin) |
|||
61R-1743 | Fitzgerald | 100 ug | 548.4 EUR |
Description: Armenian Hamster monoclonal CD80 antibody (allophycocyanin) |
|||
![]() CD80 antibody (FITC) |
|||
61R-CD80bHUFT | Fitzgerald | 120 tests | 651.6 EUR |
Description: Mouse monoclonal CD80 antibody (FITC) |
|||
![]() CD80 antibody (Allophycocyanin) |
|||
61R-CD80bMSAPC | Fitzgerald | 100 ug | 522 EUR |
Description: Rat monoclonal CD80 antibody (Allophycocyanin) |
|||
![]() CD80 antibody (biotin) |
|||
61R-CD80bMSBT | Fitzgerald | 500 ug | 495.6 EUR |
Description: Rat monoclonal CD80 antibody (biotin) |
|||
![]() CD80 antibody (FITC) |
|||
61R-CD80bMSFT | Fitzgerald | 500 ug | 548.4 EUR |
Description: Rat monoclonal CD80 antibody (FITC) |
|||
![]() CD80 antibody (PE) |
|||
61R-CD80bMSPE | Fitzgerald | 200 ug | 548.4 EUR |
Description: Rat monoclonal CD80 antibody (PE) |
|||
![]() Hamster CD80 Antibody |
|||
abx140014-01mg | Abbexa | 0.1 mg | 343.2 EUR |
![]() Anti-CD80 Antibody |
|||
A00196-1 | BosterBio | 100ug/vial | 400.8 EUR |
![]() Anti-CD80 Antibody |
|||
PA1365 | BosterBio | 100ug/vial | 352.8 EUR |
![]() Anti-CD80 Antibody |
|||
PA1365-1 | BosterBio | 100ug/vial | 352.8 EUR |
![]() anti- CD80 antibody |
|||
FNab09813 | FN Test | 100µg | 658.5 EUR |
Description: Antibody raised against CD80 |
|||
![]() Anti-CD80 antibody |
|||
PAab01500 | Lifescience Market | 100 ug | 463.2 EUR |
![]() Anti-CD80 Antibody |
|||
STJ500483 | St John's Laboratory | 100 µg | 571.2 EUR |
![]() Anti-CD80 antibody |
|||
STJ16100188 | St John's Laboratory | 100 µg | 483.6 EUR |
![]() Anti-CD80 antibody |
|||
STJ16100189 | St John's Laboratory | 100 µg | 628.8 EUR |
![]() Anti-CD80 antibody |
|||
STJ16101125 | St John's Laboratory | 100 µg | 424.8 EUR |
![]() Anti-CD80 antibody |
|||
STJ170002 | St John's Laboratory | 100 µg | 409.2 EUR |
Description: The CD80 antigen (B7, BB1) recognizes a 60 kDa transmembrane glycoprotein, member of the immunoglobulin family. This molecule shares with CD86 the capability to be the ligand for two structurally similar molecules expressed on T lymphocytes, CD28 and CD152 (CTLA-4). CD80 antigen is expressed on in vitro activated B lymphocytes. It is not expressed on the majority of resting B cells from peripheral blood but identifies a subpopulation of B cells that has been previously activated. The antigen is also expressed by HTLV-1 transformed T cells activated monocytes, and constitutively on dendritic cells. CD80 binding provides costimulatory signals for T cell activation. |
|||
![]() Anti-CD80 antibody |
|||
STJ72065 | St John's Laboratory | 100 µg | 430.8 EUR |
![]() Anti-CD80 antibody |
|||
STJ118492 | St John's Laboratory | 100 µl | 332.4 EUR |
![]() CD80 Antibody [8G12] |
|||
RF16041-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [8G12] |
|||
RF16041-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [10A1] |
|||
RF16042-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [10A1] |
|||
RF16042-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [7A2] |
|||
RF16043-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [7A2] |
|||
RF16043-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [11D1] |
|||
RF16044-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [11D1] |
|||
RF16044-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [11C12] |
|||
RF16045-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [11C12] |
|||
RF16045-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [12D9] |
|||
RF16046-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() CD80 Antibody [12D9] |
|||
RF16046-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
|||
![]() Anti-CD80 antibody |
|||
STJ98977 | St John's Laboratory | 200 µl | 236.4 EUR |
Description: Rabbit polyclonal to CD80. |
|||
![]() Anti-CD80 antibody |
|||
STJ97938 | St John's Laboratory | 100 µl | 280.8 EUR |
Description: Mouse monoclonal to CD80. |
|||
![]() CD80 siRNA |
|||
20-abx911077 | Abbexa |
|
|
![]() CD80 siRNA |
|||
20-abx911078 | Abbexa |
|
|
![]() CD80 Peptide |
|||
42-780P | ProSci | 0.1 mg | 405.6 EUR |
Description: (IN) CD80 peptide |
|||
![]() CD80 Peptide |
|||
8679P | ProSci | 0.05 mg | 197.7 EUR |
Description: CD80 Peptide |
|||
![]() anti-CD80 |
|||
YF-PA10781 | Abfrontier | 50 ug | 435.6 EUR |
Description: Mouse polyclonal to CD80 |
|||
![]() anti-CD80 |
|||
YF-PA10782 | Abfrontier | 100 ul | 483.6 EUR |
Description: Rabbit polyclonal to CD80 |
|||
![]() anti-CD80 |
|||
YF-PA10784 | Abfrontier | 100 ug | 483.6 EUR |
Description: Rabbit polyclonal to CD80 |
|||
![]() CD80 antibody (Spectral Red) |
|||
61R-CD80bMSSP | Fitzgerald | 100 ug | 535.2 EUR |
Description: Rat monoclonal CD80 antibody (Spectral Red) |
|||
![]() CD80 antibody (Azide Free) |
|||
10R-CD80bMP | Fitzgerald | 500 ug | 548.4 EUR |
Description: Rat monoclonal CD80 antibody (Azide Free) |
|||
![]() Anti-CD80 Antibody BIOTIN |
|||
STJ500484 | St John's Laboratory | 100 µg | 703.2 EUR |
![]() Anti-CD80 Antibody FITC |
|||
STJ500485 | St John's Laboratory | 100 µg | 703.2 EUR |
![]() Recombinant Rabbit B7-1/CD80 (C-6His) |
|||
CP57-10ug | Novoprotein | 10ug | 120 EUR |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
![]() Recombinant Rabbit B7-1/CD80 (C-6His) |
|||
CP57-1mg | Novoprotein | 1mg | 1155.6 EUR |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
![]() Recombinant Rabbit B7-1/CD80 (C-6His) |
|||
CP57-500ug | Novoprotein | 500ug | 850.8 EUR |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
![]() Recombinant Rabbit B7-1/CD80 (C-6His) |
|||
CP57-50ug | Novoprotein | 50ug | 169.2 EUR |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
|||
![]() Rabbit Anti-Human CD80 monoclonal antibody, clone KG21-5 |
|||
CABT-L900 | Creative Diagnostics | 100 ul | 932.4 EUR |
![]() Human T-lymphocyte activation antigen CD80 (CD80) |
|||
1-CSB-MP004959HU1 | Cusabio |
|
|
Description: Recombinant Human T-lymphocyte activation antigen CD80(CD80),partial expressed in Mammalian cell |
|||
![]() Human T-lymphocyte activation antigen CD80 (CD80) |
|||
1-CSB-CF1054HU | Cusabio |
|
|
Description: Recombinant Human T-lymphocyte activation antigen CD80(CD80) expressed in in vitro E.coli expression system |
|||
![]() Monoclonal CD80 Antibody, Clone: 2A2 |
|||
APG02506G | Leading Biology | 0.1ml | 580.8 EUR |
Description: A Monoclonal antibody against Human CD80. The antibodies are raised in Mouse and are from clone 2A2. This antibody is applicable in IHC, ICC, E |
|||
![]() CD80 Blocking Peptide |
|||
DF7682-BP | Affbiotech | 1mg | 234 EUR |
![]() CD80 Recombinant Protein |
|||
96-044 | ProSci | 0.1 mg | 619.8 EUR |
Description: B7-1 and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas. |
|||
![]() CD80 Recombinant Protein |
|||
96-045 | ProSci | 0.1 mg | 619.8 EUR |
Description: B71 and B72, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas. |
|||
![]() CD80 Recombinant Protein |
|||
96-085 | ProSci | 0.1 mg | 619.8 EUR |
Description: B7-1 and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas. |
|||
![]() CD80 Recombinant Protein |
|||
90-399 | ProSci | 100 ug | 651.3 EUR |
Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites. |
|||
![]() CD80 Recombinant Protein |
|||
90-400 | ProSci | 100 ug | 651.3 EUR |
Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites. |
|||
![]() CD80 Recombinant Protein |
|||
90-401 | ProSci | 100 ug | 651.3 EUR |
Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites. |
|||
![]() anti-CD80 (2A2) |
|||
LF-MA30281 | Abfrontier | 100 ul | 583.2 EUR |
Description: Mouse Monoclonal to CD80 |
|||
![]() B7-1/CD80 |
|||
E21-K61 | EnoGene | 10ug | 411.6 EUR |
![]() Anti-CD80 (1G1) |
|||
YF-MA12322 | Abfrontier | 100 ug | 435.6 EUR |
Description: Mouse monoclonal to CD80 |
|||
![]() Anti-CD80 (3E10) |
|||
YF-MA12323 | Abfrontier | 200 ul | 435.6 EUR |
Description: Mouse monoclonal to CD80 |
|||
![]() Anti-CD80 (4A4) |
|||
YF-MA12324 | Abfrontier | 200 ul | 435.6 EUR |
Description: Mouse monoclonal to CD80 |
|||
![]() Anti-CD80 (3D7) |
|||
YF-MA12325 | Abfrontier | 100 ug | 435.6 EUR |
Description: Mouse monoclonal to CD80 |
|||
![]() Mouse T-lymphocyte activation antigen CD80(CD80) ELISA kit |
|||
CSB-EL004959MO-24T | Cusabio | 1 plate of 24 wells | 198 EUR |
Description: Quantitative sandwich ELISA kit for measuring Mouse T-lymphocyte activation antigen CD80 (CD80) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
|||
![]() Mouse T-lymphocyte activation antigen CD80(CD80) ELISA kit |
|||
1-CSB-EL004959MO | Cusabio |
|
|
Description: Quantitative sandwich ELISA kit for measuring Mouse T-lymphocyte activation antigen CD80(CD80) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
|||
![]() Human CD80/ T-lymphocyte activation antigen CD80 ELISA Kit |
|||
E0441Hu | Sunlong | 1 Kit | 675.6 EUR |
![]() Human CD80(T-lymphocyte activation antigen CD80) ELISA Kit |
|||
EH0088 | FN Test | 96T | 681.12 EUR |
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 46.9pg/ml |
|||
![]() Human T- lymphocyte activation antigen CD80, CD80 ELISA KIT |
|||
ELI-06511h | Lifescience Market | 96 Tests | 988.8 EUR |
![]() Mouse T- lymphocyte activation antigen CD80, Cd80 ELISA KIT |
|||
ELI-06512m | Lifescience Market | 96 Tests | 1038 EUR |
![]() Rat Anti Mouse Cd80 Monoclonal Antibody |
|||
CABT-46717RM | Creative Diagnostics | 0.1 mg | 546 EUR |
![]() Mouse Anti-Human CD80 mAbConjugated Antibody |
|||
CCM015 | SAB | 100ul | 476.4 EUR |
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC941608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF594 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC941608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF594 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCA1608-250 | Biotium | 250uL | 459.6 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),APC conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC551608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF555 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC551608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF555 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC611608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF660R conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC611608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF660R conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNUM1608-50 | Biotium | 50uL | 474 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608), 1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCP1608-250 | Biotium | 250uL | 459.6 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),PerCP conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCR1608-250 | Biotium | 250uL | 459.6 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),RPE conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC431608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF543 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC431608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF543 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC051608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405M conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC051608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405M conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC401608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF640R conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC401608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF640R conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC811608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680R conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC811608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680R conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC801608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC801608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF680 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCH1608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCH1608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC041608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405S conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC041608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF405S conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC681608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF568 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC681608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF568 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC701608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF770 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC701608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF770 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCAP1608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCAP1608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC881608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF488A conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC881608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF488A conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCB1608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),Biotin conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNCB1608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),Biotin conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC471608-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF647 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNC471608-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608),CF647 conjugate, Concentration: 0.1mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNUB1608-100 | Biotium | 100uL | 250.8 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608), Concentration: 0.2mg/mL |
|||
![]() CD80 (B7-1) (C80/1608) Antibody |
|||
BNUB1608-500 | Biotium | 500uL | 549.6 EUR |
Description: Primary antibody against CD80 (B7-1) (C80/1608), Concentration: 0.2mg/mL |
|||
![]() Cluster of differentiation 80 (CD80) Antibody |
|||
20-abx111494 | Abbexa |
|
|
![]() Cluster of differentiation 80 (CD80) Antibody |
|||
20-abx210922 | Abbexa |
|
|
![]() Cluster of differentiation 80 (CD80) Antibody |
|||
20-abx339272 | Abbexa |
|
|
![]() Cluster of differentiation 80 (CD80) Antibody |
|||
20-abx323191 | Abbexa |
|
|
![]() Cd80 ELISA Kit| Mouse T-lymphocyte activation antigen CD80 ELIS |
|||
EF014437 | Lifescience Market | 96 Tests | 826.8 EUR |
![]() Mouse CD80 shRNA Plasmid |
|||
20-abx969582 | Abbexa |
|
|
CD80 Rabbit Polyclonal Antibody